Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 01:16PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-11.71 Insider Own30.55% Shs Outstand2.18M Perf Week-4.45%
Market Cap7.37M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.70M Perf Month3.88%
Income-26.54M PEG- EPS next Q- Inst Own43.75% Short Float1.58% Perf Quarter40.00%
Sales0.61M P/S12.09 EPS this Y- Inst Trans25.86% Short Ratio3.39 Perf Half Y-17.53%
Book/sh5.26 P/B0.57 EPS next Y- ROA-120.49% Short Interest0.03M Perf Year-81.02%
Cash/sh3.72 P/C0.81 EPS next 5Y- ROE-165.04% 52W Range1.75 - 13.78 Perf YTD-10.15%
Dividend Est.- P/FCF- EPS past 5Y21.62% ROI-206.14% 52W High-78.15% Beta1.78
Dividend TTM- Quick Ratio4.21 Sales past 5Y-9.04% Gross Margin- 52W Low71.99% ATR (14)0.33
Dividend Ex-Date- Current Ratio4.21 EPS Y/Y TTM46.62% Oper. Margin-3510.53% RSI (14)48.23 Volatility17.69% 9.76%
Employees16 Debt/Eq0.00 Sales Y/Y TTM-60.77% Profit Margin-4364.64% Recom1.00 Target Price80.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q30.35% Payout- Rel Volume0.11 Prev Close3.11
Sales Surprise-13.92% EPS Surprise-3.33% Sales Q/Q- Earnings- Avg Volume7.91K Price3.01
SMA200.19% SMA50-10.49% SMA200-15.15% Trades Volume595 Change-3.22%
Date Action Analyst Rating Change Price Target Change
Oct-20-21Initiated Truist Buy $14
Sep-24-21Initiated Cantor Fitzgerald Overweight $7
Jun-03-19Initiated Credit Suisse Neutral
Dec-04-23 08:00AM
Nov-30-23 06:16PM
Aug-02-23 08:39PM
Jul-31-23 07:00AM
Jun-01-23 04:00PM
01:00PM Loading…
May-15-23 01:00PM
May-12-23 02:59PM
May-11-23 06:00PM
Apr-03-23 07:30AM
Mar-27-23 07:00AM
Mar-22-23 04:40PM
Nov-22-22 07:00AM
Nov-09-22 06:34AM
Oct-07-22 02:31PM
12:46PM Loading…
Oct-06-22 12:46PM
Aug-09-22 05:35PM
Aug-08-22 09:22AM
Jul-28-22 07:00AM
Jul-26-22 07:00AM
Jun-28-22 09:00AM
Jun-22-22 08:30AM
Jun-17-22 11:20AM
Jun-10-22 07:00AM
Jun-06-22 07:00AM
May-11-22 09:30AM
May-04-22 04:01PM
06:39AM Loading…
Feb-27-22 06:39AM
Feb-24-22 04:01PM
Feb-23-22 08:00AM
Feb-01-22 05:30AM
Jan-26-22 08:00AM
Dec-15-21 10:00AM
Nov-25-21 04:47AM
Nov-11-21 05:32PM
Nov-09-21 04:01PM
Nov-08-21 12:00PM
Oct-20-21 04:24PM
Oct-11-21 03:34AM
Oct-10-21 09:37AM
Sep-22-21 08:00AM
Sep-08-21 08:00AM
Aug-26-21 07:19AM
Aug-23-21 05:00PM
Jul-29-21 05:00PM
Jul-22-21 04:30PM
Jul-12-21 02:24AM
Jul-09-21 06:14AM
Jul-08-21 07:22PM
Jun-04-21 10:27AM
May-27-21 04:30PM
May-25-21 07:00AM
May-09-21 03:36AM
Apr-27-21 09:00AM
Apr-26-21 07:00AM
Apr-21-21 07:30AM
Apr-20-21 07:00AM
Mar-24-21 04:05PM
Mar-22-21 02:23AM
Mar-19-21 07:46AM
Mar-18-21 05:00PM
Feb-25-21 07:00AM
Jan-25-21 07:00AM
Jan-21-21 12:52AM
Jan-04-21 07:00AM
Dec-21-20 07:30AM
Dec-02-20 11:27PM
Nov-15-20 07:55AM
Nov-05-20 07:00AM
Oct-14-20 01:09PM
Oct-04-20 09:52AM
Sep-04-20 07:00AM
Aug-25-20 07:00AM
Aug-20-20 11:01AM
Aug-03-20 09:25AM
Jul-30-20 09:00AM
Jul-17-20 07:00AM
Jul-06-20 03:17PM
Jul-05-20 02:45PM
Jun-18-20 04:01PM
May-22-20 07:52AM
Apr-10-20 07:00AM
Mar-23-20 06:50AM
Jan-13-20 07:00AM
Jan-12-20 05:05PM
Dec-24-19 08:17AM
Dec-23-19 07:00AM
Dec-12-19 03:43PM
Nov-27-19 07:00AM
Nov-01-19 10:52AM
Oct-31-19 08:08AM
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCGUIRE TERRANCEDirectorAug 09Sale3.408270Aug 11 04:25 PM